Company intelligence / Profile preview

Bolder

Boulder, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Bolder BioTechnology has completed a Phase 1 clinical trial of BBT-015, a long-acting G-CSF analog, in healthy volunteers, reporting positive results. Its BBT-059 (long-acting IL-11 analog) received FDA Orphan Drug designation for Acute Radiation Syndrome. Most programs remain in preclinical or IND-enabling stages[1][2][7].

Therapeutic areas: EndocrinologyInfectious DiseasesHematologyOncologyNeurology
Modalities: ProteinRecombinant proteinCytokineLong-acting protein analog
Industry: Biotech

Partnerships

NIH SBIR grants (R&D funding)

Beyond the preview

Go deeper on Bolder.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bolder.

Explore the full profile